Lupin Ltd.
Clinical trials sponsored by Lupin Ltd., explained in plain language.
-
New study tracks heart and skin risks of muscle drug in toddlers
Disease control Recruiting nowThis study follows up to 10 children from birth to under 6 years old who have genetic muscle stiffness disorders (myotonic disorders) and are taking mexiletine. Researchers will monitor side effects like heart rhythm problems and severe skin reactions over time. The goal is to un…
Sponsor: Lupin Ltd. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New Slow-Release drug may ease muscle stiffness with fewer side effects
Symptom relief Recruiting nowThis study tests whether a slow-release form of mexiletine (PR) works as well as the standard immediate-release form (IR) for easing muscle stiffness in people with non-dystrophic myotonias. About 24 adults will take both versions in a random order to compare safety and side effe…
Phase: PHASE3 • Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated May 17, 2026 09:19 UTC
-
New hope for muscle stiffness: once-daily pill tested in myotonic dystrophy
Symptom relief Recruiting nowThis study tests whether a once-daily medication called mexiletine can safely reduce muscle stiffness (myotonia) in people with myotonic dystrophy types 1 and 2. About 176 adults aged 16 and older will receive either the drug or a placebo for 26 weeks. The main goal is to see if …
Phase: PHASE3 • Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated May 05, 2026 11:55 UTC